Evidence map›Paper›PMID 42045322›Full record

ArticleScientific reports2026

miR-30b-5p suppresses prostate cancer progression by targeting FLVCR1 through the cAMP/PKA/CREB pathway.

Dong Shi, Yurui Tang, Chong Lu, Haoran Yang, Wei He

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dong ShiDepartment of Urology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China.
Yurui TangDepartment of Urology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China.
Chong LuDepartment of Urology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China.
Haoran YangDepartment of Urology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China.
Wei HeDepartment of Urology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China. ch1992640003@fy.ahmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs are key post-transcriptional regulators implicated in tumor biology. Emerging evidence suggests that miR-30b-5p functions as a tumor suppressor in several human cancers; however, its contribution to prostate cancer remains poorly defined. Here, we report that miR-30b-5p expression is significantly reduced in prostate cancer tissues and cell lines, and its downregulation is closely associated with aggressive clinicopathological characteristics. Gain- and loss-of-function assays revealed that miR-30b-5p inhibits prostate cancer cell proliferation, migration, and invasion, while promoting apoptosis in vitro, and suppresses tumor growth in vivo. FLVCR1 was identified and validated as a downstream target of miR-30b-5p through bioinformatics prediction and luciferase reporter analysis. Mechanistically, FLVCR1 enhances malignant progression by activating the cAMP signaling pathway, and this oncogenic effect is markedly attenuated by ZnPP treatment. Collectively, our findings establish miR-30b-5p as a functional tumor suppressor that restricts prostate cancer progression by repressing FLVCR1-mediated cAMP signaling. miR-30b-5p may serve as a promising prognostic indicator and therapeutic target for patients with prostate cancer.

Indexed as

Cyclic AMPCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinMicroRNAsProstatic NeoplasmsSignal TransductionAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansMaleMiceCyclic AMPCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinMicroRNAsMIRN30b microRNA, humanFLVCR1miR-30b-5pProgressionProstate cancerThe cAMP/PKA/CREB pathway

Identifiers

PMID42045322
PMCPMC13287586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.